Lovastatin TABLET

Get an overview of LOVASTATIN (tablet), including its generic name, formulation (i.e. pill, oral solution, injection, inhaled medicine) and why it’s used. The medication in Lovastatin can be sold under different names.

Refer to the “Also Known As” section to reference different products that include the same medication as Lovastatin.

Drug Basics

Brand Name: Lovastatin

Generic Name: LOVASTATIN

Drug Type: HUMAN PRESCRIPTION DRUG

Route: ORAL

Dosage Form: TABLET

Data Current As Of: 2018-10-11

Rx only

indications & usage

Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk.

primary prevention of coronary heart disease

In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of:

- Myocardial infarction

- Unstable angina

- Coronary revascularization procedures

(See CLINICAL PHARMACOLOGY, Clinical Studies)

coronary heart disease

Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels.

hypercholesterolemia

Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate.

____________________________________________________

2Classification of Hyperlipoproteinemias

Lipid Elevations

Type

Lipoproteins Elevated

Major

Minor

I

chylomicrons

TG

↑→C

IIa

LDL

C

IIb

LDL, VLDL

C

TG

III (rare)

IDL

C/TG

IV

VLDL

TG

↑→C

V (rare)

chylomicrons, VLDL

TG

↑→C

IDL = intermediate-density lipoprotein.

adolescent patients with heterozygous familial hypercholesterolemia

Lovastatin tablets USP are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present:

1. LDL-C remains >189 mg/dL or

  • 2. LDL-C remains >160 mg/dL and:
    • there is a positive family history of premature cardiovascular disease or
  • two or more other CVD risk factors are present in the adolescent patient

general recommendations

Prior to initiating therapy with lovastatin tablets USP, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation:

LDL-C = total-C - [0.2 x (TG) + HDL-C]

For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets USP are not indicated.

The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below:

NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories

Risk Category

LDL Goal
(mg/dL)

LDL Level at Which to Initiate Therapeutic Lifestyle Changes
(mg/dL)

LDL Level at Which to Consider Drug Therapy
(mg/dL)

CHD

CHD, coronary heart disease

or CHD risk equivalents
(10-year risk >20%)

<100

≥100

≥130
(100-129: drug optional)

Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory.

2+ Risk factors
(10-year risk ≤20%)

<130

≥130

10-year risk 10-20%: ≥130
10-year risk <10%: ≥160

0-1 Risk factor

Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary.

<160

≥160

≥190
(160-189: LDL-lowering drug optional)

After the LDL-C goal has been achieved, if the TG is still >200 mg/dL, non HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category.

At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is >130 mg/dL (see NCEP Guidelines above).

Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy.

Although lovastatin tablets USP may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V). 2

2 Classification of Hyperlipoproteinemias

The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below:

Category

Total-C (mg/dL)

LDL-C (mg/dL)

Acceptable

<170

<110

Borderline

170 to 199

110 to 129

High

≥200

≥130

Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C.

contraindications

Hypersensitivity to any component of this medication.

Active liver disease or unexplained persistent elevations of serum transaminases (see WARNINGS ).

Concomitant administration with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, and cobicistat-containing products) (see WARNINGS, Myopathy/Rhabdomyolysis ).

pregnancy & lactation

(See PRECAUTIONS, Pregnancy and Nursing Mothers ).

Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. Because of the ability of inhibitors of HMG-CoA reductase such as lovastatin to decrease the synthesis of cholesterol and possibly other products of the cholesterol biosynthesis pathway, lovastatin is contraindicated during pregnancy and in nursing mothers. Lovastatin should be administered to women of childbearing age only when such patients are highly unlikely to conceive. If the patient becomes pregnant while taking this drug, lovastatin should be discontinued immediately and the patient should be apprised of the potential hazard to the fetus (see PRECAUTIONS, Pregnancy ).

also known as

This drug label information is as submitted to the Food and Drug Administration (FDA) and is intended for informational purposes only. If you think you may have a medical emergency, immediately call your doctor or dial 911. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Search Drugs and Medication

Or Browse by Name

Top Reads

Love the Doctor Who Prescribed This Medication?

Top Drugs
  • Antibiotic, antifungal and antiviral drugs treat infectious diseases. They kill or stop the growth of microorganisms, including bacteria, fungi and viruses.
  • Birth control medications are a form of contraception. They contain either a combination of estrogen and progestin or progestin alone. There are several forms of these hormones, but most combination products contain estrogen, ethinyl estradiol, and a progestin. They work by preventing ovulation and inhibiting fertilization and implantation.
  • Mental health drugs treat conditions that affect emotional, psychological and social well-being. Doctors frequently use mental health drugs in combination with various forms of therapy to help people manage these conditions.
  • Arthritis medications and muscle relaxers treat problems with the musculoskeletal system. These include injuries and conditions affecting the joints, muscles, and other soft tissues that help the body flex and move.